{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T03:49:08Z","timestamp":1772768948087,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clml.2025.08.020","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T15:45:37Z","timestamp":1756914337000},"page":"e62-e76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["International Prognostic Models as Tools for Selection of Higher-risk Trial-eligible Patients With Diffuse Large B-Cell lymphoma"],"prefix":"10.1016","volume":"26","author":[{"given":"Jelena","family":"Jelicic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Juul-Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoran","family":"Bukumiric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1119-4782","authenticated-orcid":false,"given":"Mikkel","family":"Runason Simonsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3218-3633","authenticated-orcid":false,"given":"Michael","family":"Roost Clausen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8739-0421","authenticated-orcid":false,"given":"Ahmed","family":"Ludvigsen Al-Mashhadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Schou Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian Bj\u00f8rn","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Ortved","family":"Gang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarec Christoffer","family":"El-Galaly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8418-6708","authenticated-orcid":false,"given":"Thomas","family":"Stauffer Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.clml.2025.08.020_bib0001","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma. Longo DL, ed","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.clml.2025.08.020_bib0002","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1182\/blood.2023020779","article-title":"DLBCL: who is high risk and how should treatment be optimized?","volume":"144","author":"Dabrowska-Iwanicka","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.08.020_bib0003","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2025.08.020_bib0004","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.08.020_bib0005","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/blood.2023023789","article-title":"The current landscape of frontline large B-cell lymphoma trials","volume":"145","author":"Qualls","year":"2025","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2025.08.020_bib0006","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(12)70481-3","article-title":"Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)","volume":"13","author":"Schmitz","year":"2012","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.clml.2025.08.020_bib0007","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the Phase III Intergroup Trial Alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.08.020_bib0008","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","article-title":"Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial","volume":"20","author":"Davies","year":"2019","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.clml.2025.08.020_bib0009","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.23.00033","article-title":"Differential efficacy from the addition of Bortezomib to R-CHOP in diffuse large B-cell lymphoma according to the molecular subgroup in the REMoDL-B study with a 5-year follow-up","volume":"41","author":"Davies","year":"2023","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.clml.2025.08.020_bib0010","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of Ibrutinib and Rituximab plus cyclophosphamide, doxorubicin, Vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.08.020_bib0011","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.08.020_bib0012","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s00277-023-05551-5","article-title":"How to improve RCHOP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of 21 randomized controlled trials","volume":"103","author":"Intzes","year":"2024","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.clml.2025.08.020_bib0013","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/bjh.17436","article-title":"Evolution of eligibility criteria for diffuse large B-cell lymphoma randomised controlled trials over 30 years","volume":"193","author":"Loh","year":"2021","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2025.08.020_bib0014","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1080\/10428194.2023.2298705","article-title":"Challenges identifying DLBCL patients with poor outcomes to upfront chemoimmunotherapy and its impact on frontline clinical trials","volume":"65","author":"Atallah-Yunes","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"10.1016\/j.clml.2025.08.020_bib0015","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2017.76.5198","article-title":"Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials","volume":"36","author":"Maurer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.clml.2025.08.020_bib0016","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1080\/10428194.2024.2390561","article-title":"The impact of trial inclusion criteria on outcomes in DLBCL patients treated with R-CHOP in the first line: a Danish nationwide study","volume":"65","author":"Simonsen","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.clml.2025.08.020_bib0017","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clml.2025.08.020_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157999","article-title":"The danish national lymphoma registry: coverage and data quality","volume":"11","author":"Arboe","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.clml.2025.08.020_bib0019","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1053\/j.ajkd.2013.12.006","article-title":"GFR estimation: from physiology to public health","volume":"63","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"27","key":"10.1016\/j.clml.2025.08.020_bib0020","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.08.020_bib0021","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"7309","key":"10.1016\/j.clml.2025.08.020_bib0022","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/bmj.323.7309.391","article-title":"Mann-Whitney test is not just a test of medians: differences in spread can be important","volume":"323","author":"Hart","year":"2001","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.clml.2025.08.020_bib0023","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/ndt\/gfq018","article-title":"Statistical methods for the assessment of prognostic biomarkers (Part I): discrimination","volume":"25","author":"Tripepi","year":"2010","journal-title":"Nephrol Dialysis Transplant"},{"issue":"10","key":"10.1016\/j.clml.2025.08.020_bib0024","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/sim.4154","article-title":"On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data","volume":"30","author":"Uno","year":"2011","journal-title":"Stat Med"},{"issue":"6","key":"10.1016\/j.clml.2025.08.020_bib0025","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2025.08.020_bib0026","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1080\/10428194.2022.2102620","article-title":"Generalizability of landmark clinical trials in diffuse large B cell lymphoma to real-world patients: a single-center retrospective cohort study","volume":"63","author":"Davidson","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"10.1016\/j.clml.2025.08.020_bib0027","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1200\/JCO.20.01935","article-title":"Impact of organ function-based clinical trial eligibility criteria in patients with diffuse large B-cell lymphoma: who gets left behind?","volume":"39","author":"Khurana","year":"2021","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clml.2025.08.020_bib0028","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.2019002729","article-title":"International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI","volume":"135","author":"Ruppert","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.08.020_bib0029","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.3109\/10428194.2015.1010078","article-title":"A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish Lymphoma Registry","volume":"56","author":"Gang","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2025.08.020_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2018.10.006","article-title":"Available prognostic models for risk stratification of diffuse large B cell lymphoma patients: a systematic review","volume":"133","author":"Jelicic","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10.1016\/j.clml.2025.08.020_bib0031","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/ejh.14275","article-title":"Effectiveness of R-CHOP versus R-CHOEP for treatment of young patients with high-risk diffuse large B-cell lymphoma: a Danish observational population-based study","volume":"113","author":"Rask Kragh J\u00f8rgensen","year":"2024","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2025.08.020_bib0032","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/mdr058","article-title":"R-choep-14 improves overall survival in young high-risk patients with diffuse large b-cell lymphoma compared with r-chop-14. a population-based investigation from the danish lymphoma group","volume":"23","author":"Gang","year":"2012","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.clml.2025.08.020_bib0033","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1038\/s41375-024-02420-6","article-title":"Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trials","volume":"38","author":"Lenz","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2025.08.020_bib0034","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/ejh.14301","article-title":"A real-world data-based analysis of prognostic indices as part of trial eligibility criteria in diffuse large B-cell lymphoma patients","volume":"114","author":"Jelicic","year":"2025","journal-title":"Eur J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.08.020_bib0035","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1182\/blood-2023-187350","article-title":"The presence of bulky disease and\/or very high LDH defines a high-risk subset of IPI 1-2 for eligibility in clinical trials of newly diagnosed aggressive B-cell lymphoma","volume":"142","author":"Maurer","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.08.020_bib0036","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1182\/bloodadvances.2020001518","article-title":"Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis","volume":"4","author":"Lepp\u00e4","year":"2020","journal-title":"Blood Adv"},{"issue":"1127","key":"10.1016\/j.clml.2025.08.020_bib0037","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210448","article-title":"Total tumor burden in lymphoma - an evolving strong prognostic parameter","volume":"94","author":"Meignan","year":"2021","journal-title":"Br J Radiol"},{"issue":"4","key":"10.1016\/j.clml.2025.08.020_bib0038","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.clml.2025.08.020_bib0039","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.clml.2024.08.010","article-title":"Analysis of histologic, immunohistochemical and genomic features of large B cell lymphoma tumors may predict response to Polatuzumab vedotin based therapy in patients with relapsed\/refractory disease","volume":"25","author":"Schneider","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"25","key":"10.1016\/j.clml.2025.08.020_bib0040","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1182\/blood.2023022048","article-title":"Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis","volume":"142","author":"Russler-Germain","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.08.020_bib0041","first-page":"1121","article-title":"Clinical endpoints in oncology-a primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am J Cancer Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025028897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025028897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T10:54:19Z","timestamp":1768388059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025028897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2152265025028897"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.08.020","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"International Prognostic Models as Tools for Selection of Higher-risk Trial-eligible Patients With Diffuse Large B-Cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}